XTLB XTL Biopharmaceuticals (XTLB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001023549
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter
XTL Biopharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for XTL BIOPHARMACEUTICALS LTD in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch XTLB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns XTLB: institutional holders (13F)
13F holdings, latest reported quarter
6,228 sh
$17.0K
1,213 sh
$3.3K
125 sh
$341
Congress trades in XTLB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
XTLB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
XTLB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$5.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
XTLB financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-12 | 2023-12 | 2022-12 | 2021-12 | |
|---|---|---|---|---|
| Gross profit | $3.0K | n/a | n/a | n/a |
| Net income | -$1.0M | -$1.8M | -$1.3M | $435.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
XTLB Stock Sonar score 1/7 axes
Find similar shapesCompare1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
